PF 477736 is a Selective and ATP-Competitive Inhibitor of Chk1
Cancer is a multiplicity of diseases characterized by a range of molecular defects leading to unregulated, aberrant cell growth. Checkpoints are present in all phases of the cell cycle. Checkpoints act as gatekeepers maintaining the integrity of the genome. Researchers use anti-tumor agents to treat cancer by imparting damage...
SAR-020106 is an ATP-Competitive and Selective CHK1 Inhibitor
Genotoxic antitumor drugs cause DNA damage and activate cell cycle checkpoints, which are required for DNA repair and the maintenance of genomic integrity. The transcription factor p53 is a critical checkpoint protein. As a result, in the presence of damaged DNA, p53 stabilized and activated, causes the upregulation of...
SB-218078 is an ATP Competitive and Reversible Chk1 Inhibitor
Research from Jeffrey R. Jackson, et al. discovered and identified an indolocarbazole inhibitor of human checkpoint Kinase (Chk1) SB-218078. SB-218078 is an ATP Competitive and Reversible Chk1 Inhibitor The regulation of cell cycle checkpoints is a critical determinant of the manner in which tumor cells in response to chemotherapies...